Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Hollis Eden Pharmaceuticals Inc. (HEPH) -- Ignore unavailable to you. Want to Upgrade?

To: BDR who wrote (60)	4/2/1998 3:10:00 PM
From: Biojunkie	Respond to of 138

I don't know if that is the doctor. The Feb.9 press release said. The company recently developed PPB2 ( trade name Inactivin ), a new analog of the company's lead drug candidate that has a unique mechanism of action for antiretroviral treatment in HIV/AIDS and other infectious diseases. PPB2 has demontrated a 10-fold increase in antiretroviral potency over the intitial anolog of Inactivin. The SEC information you are talking about was probubly the company's initial anolog DHEA. It appears to me that PPB2 is a new compound using the same trade name Inactivin. I'm a little confused, why you don't look at the company's most recent information.